This opportunity is no longer accepting applications.
grant PAR-23-314

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

The National Cancer Institute (NCI) is offering a funding opportunity to support the validation of biomarkers and assays used in cancer detection and treatment. The focus is on accelerating the adoption of these tools for various purposes, such as predicting treatment responses and monitoring cancer progression. Applicants must have analytically validated assays suitable for clinical use. The …

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and predict…

Funding Source

Agency: National Institutes of Health
Program: SBIR

Awards & funding

Award Ceiling: $250,000
Award Amount: $250,000

Dates

Opportunity Released: October 31, 2023
Open for Submission: October 31, 2023
Submission Deadline: October 14, 2026
Application Window Closes: October 14, 2026

Documents

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.